Brief: Soleno Therapeutics Inc - FDA Approves Soleno's Vykat XR For Hyperphagia In Prader-Willi Syndrome - SEC Filing
26/03/2025 21:03
March 26 (Reuters) - Soleno Therapeutics Inc SLNO.O: SOLENO THERAPEUTICS INC - FDA APPROVES SOLENO'S VYKAT XR FOR HYPERPHAGIA IN PRADER-WILLI SYNDROME - SEC FILING SOLENO THERAPEUTICS INC - VYKAT XR EXPECTED TO BE AVAILABLE IN U.S. FROM APRIL 2025 - SEC FILING Source text: [ID:n0001193125-25-064140] Further company coverage: SLNO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Soleno Therapeutics
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: EMA's CHMP Recommends Granting A Marketing Authorisation For Cenrifki (Tolebrutinib)